ELTX

ELTX

USD

Elicio Therapeutics Inc. Common Stock

$5.500+0.260 (4.962%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$5.240

高値

$5.750

安値

$5.130

出来高

0.00M

企業ファンダメンタルズ

時価総額

87.7M

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.04M

取引所

NCM

通貨

USD

52週レンジ

安値 $3.342現在値 $5.500高値 $11.45

AI分析レポート

最終更新: 2025年5月1日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

ELTX (Elicio Therapeutics Inc. Common Stock): What's Happening with the Stock and What to Watch For

Stock Symbol: ELTX Generate Date: 2025-05-01 06:12:05

Let's break down what's been going on with Elicio Therapeutics stock based on the latest information. We'll look at the news, how the price has been moving, and what some predictions suggest.

Recent News Buzz

Okay, so what's the general feeling from the recent news about Elicio? It seems pretty positive overall.

First off, the company brought in a new Chief Strategy and Financial Officer, plus some other new folks. That kind of news usually suggests the company is building out its team and operations, which can be a good sign for stability and future plans.

Then, a firm called HC Wainwright & Co. came out and said they still like the stock, keeping their "Buy" rating and a $10 price target. Getting a thumbs-up from analysts, especially with a price target well above where the stock is trading now, is definitely seen as a positive signal in the market.

Finally, Elicio shared their 2024 financial results and gave updates on their work. The big news here is they finished signing up patients for a key Phase 2 study (AMPLIFY-7P). They also mentioned they're on the same page with the FDA about important parts of their plan. Finishing enrollment and getting FDA alignment are significant steps forward for a biotech company, suggesting their clinical trials are progressing.

So, putting it together, the news flow points towards operational strengthening, positive analyst sentiment, and good progress on the clinical trial front.

Price Check

Now, let's look at what the stock price itself has been doing. If you look at the last few months, it's been a bit of a rough ride. The price was trading up around $9 or more back in February, but it's seen a pretty significant drop since then. There was a particularly sharp fall around the end of March and early April.

Lately, though, in the latter half of April, the price seems to have settled into a range, mostly trading between roughly $4.70 and $5.30. The last recorded price (Previous Close) was $4.81, which is right in that recent trading zone.

What about the very near future? An AI prediction tool suggests the price might stay flat today but then potentially tick up a bit over the next couple of days, maybe gaining a few percent.

Outlook & Ideas

So, we have positive news updates and analyst support, but the stock price has taken a big hit recently, although it seems to be stabilizing. The AI predicts a small upward move soon.

This situation is a bit mixed because of that large prior price drop. However, the recent positive news and the AI's short-term forecast lean towards a potential stabilization or even a slight bounce from current levels. It doesn't scream "sell," and the positive developments could attract attention.

If someone were considering this stock, where might they look? Given the recent trading range and the AI's prediction of a slight rise, the current price area around $4.81, or perhaps slightly higher up to the $5.09 mark (as suggested by some recommendation data), could be seen as potential entry points if you believe the positive news and AI prediction will lead to a bounce.

What about managing risk? If the price doesn't move up and instead continues to fall, a stop-loss order around $4.33 (again, referencing recommendation data) could be a way to limit potential losses. That level is below the recent lows we've seen. On the upside, if the stock does climb, a potential take-profit target might be around $5.18, which aligns with the recent trading range high and the AI's predicted short-term move. These are just ideas for managing potential outcomes.

Company Context

It's important to remember that Elicio Therapeutics is a clinical-stage biotechnology company. This means their main focus is developing new medicines, particularly for cancer treatments. Because of this, news about their clinical trials, results, and interactions with regulatory bodies like the FDA are incredibly important and can cause big swings in the stock price.

Also, keep in mind it's a smaller company with a market value under $80 million and relatively low daily trading volume. This means that even a moderate amount of buying or selling activity can have a noticeable impact on the share price, potentially leading to more volatility compared to larger, more heavily traded stocks.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Investing in stocks involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

関連ニュース

GlobeNewswire

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the

もっと見る
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics with a Buy and maintains $10 price target.

もっと見る
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target
GlobeNewswire

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival ("DFS") event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration ("FDA") on key elements of

もっと見る
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

AI予測Beta

AI推奨

強気

更新日時: 2025年5月5日 12:35

弱気中立強気

65.2% 信頼度

リスクと取引

リスクレベル4/5
高リスク
適しているのは
バリュー
取引ガイド

エントリーポイント

$5.50

利確

$5.88

損切り

$4.87

主要因子

K値18.8はD値22.5を下回り20以下であり、売られすぎの状態を示唆しています
DMIは弱気トレンドを示しており (ADX:25.1、+DI:32.6、-DI:33.7)、注意が必要です
現在の価格はサポートレベル(5.46ドル)に非常に接近しており、強力な買い機会を示唆しています
MACD 0.0968はシグナルライン0.1287の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。